Device and method for non-invasive collection of colorectal mucocellular layer and disease detection
The present invention relates to a device and a method for collecting a sample of colorectal mucocellular layer excreted immediately following the natural act of defaecation from the surface of the anal area of a human subject, and preservation and analysis of the collected sample for detecting diagnostically informative disease biomarkers.
1. A non-invasive method for collecting a sample of intestinal or bowel cells or cell fragments comprising:
taking a swab of mucocellular layer material that originates from said bowel or intestine and is excreted during defaecation, from the exterior surface of the anal area in the vicinity of the exterior opening of the anal canal, wherein said swab is taken following defaecation; and
(a) collecting the sample of intestinal or bowel cells or cell fragments from the swab of mucocellular layer material, wherein collecting includes transferring the sample of intestinal or bowel cells or cell fragments from the swab of mucocellular layer material into a medium for sample storage or lysis; and analysing said mucocellular layer material from said sample for the presence of one or more bowel disease-specific markers or analyzing cell morphology of the mucocellular layer material; or
(b) collecting a sample of intestinal or bowel cells or cell fragments from the swab of mucocellular layer material and analyzing cell morphology of the mucocellular layer material.
2. A method as claimed in claim 1 wherein the swab is taken within 5 minutes of defaecation and prior to cleaning the anal area.
3. A method as claimed in claim 1 wherein if (b), then further comprising placing said swab of mucocellular layer material in a storage or lysis medium.
4. A method as in claim 1 , wherein if (b), then wherein the method further comprises analysing said sample for the presence of one or more bowel disease-specific markers.
5. A method as claimed in claim 4 wherein said analysing comprises analysing the cell morphology and/or detecting the presence of and/or quantitatively or semi-quantitatively measuring one or more disease-specific molecular markers.
6. A method for screening for or diagnosing bowel disease using the method of claim 1 .
7. A method for monitoring bowel disease using the method of claim 1 .
8. A method as claimed in claim 1 , wherein the bowel disease is selected from the group consisting of colorectal cancer, inflammatory bowel disease, anal cancer and advanced colorectal polyps.
9. A method as claimed in claim 1 wherein said swab comprises a porous sample collection material coupled to a lateral flow assay system.
10. A method as claimed in claim 1 wherein said medium for lysis further comprises oligonucleotide primers specific for bowel disease-specific genetic markers and reagents for performing isothermal PCR.
11. A method as claimed in claim 1 wherein the swab further comprises a gel plug.
12. A method as claimed in claim 9 , wherein said swab further comprises a sample holder with a cap, wherein said lateral assay system comprises a lateral assay strip between said cap and said sample collection material and wherein said cap includes a system to promote capillary action.
13. A method of assessing the efficiency of bowel disease treatment using the method described in claim 1 .
14. A method as claimed in claim 13 , further comprising evaluating the level of activity of bowel inflammation.
15. A method as claimed in claim 3 , wherein the storage medium comprises a concentrated salt solution.
16. A method as claimed in claim 3 , wherein the storage medium is a liquid or gel.
17. A method as claimed in claim 15 , wherein the storage medium is a liquid or gel.
18. A method as claimed in claim 15 , wherein said salt solution is ammonium sulphate.
19. A method as claimed in claim 15 , wherein said salt solution is non-saturated.
20. A method as claimed in claim 16 , wherein the storage medium is a gel, and wherein the gel further comprises a gelling agent.
21. A method as claimed in claim 20 , wherein the gel comprises no more than 25% ammonium sulphate v/v and no more than 0.25% agarose w/v.
22. A method as claimed in claim 6 , wherein the bowel disease is selected from the group consisting of colorectal cancer, inflammatory bowel disease, anal cancer and advanced colorectal polyps.
23. A method as claimed in claim 7 , wherein the bowel disease is selected from the group consisting of colorectal cancer, inflammatory bowel disease, anal cancer and advanced colorectal polyps.
24. A method as claimed in claim 9 , wherein said porous sample collection material is flocked nylon.
25. A method as claimed in claim 9 , wherein said assay system is an immunoassay or a nucleic acid hybridisation assay.
26. A method as claimed in claim 9 , wherein said assay system comprises at least one test line.